Ono Pharmaceutical (OTCMKTS:OPHLF) Shares Down 7.1% – Should You Sell?

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) shares dropped 7.1% during mid-day trading on Friday . The stock traded as low as $14.45 and last traded at $14.45. 256 shares were traded during trading, a decline of 40% from the average daily volume of 429 shares. The stock had previously closed at $15.56.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Trading Up 0.4%

The company’s 50 day moving average price is $14.42 and its two-hundred day moving average price is $14.70. The stock has a market capitalization of $6.79 billion, a PE ratio of 14.60 and a beta of 0.34. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.02 and a quick ratio of 2.56.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.